Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014117 | 0.76 | OPRL1 (0.59) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3205899 | 0.73 | OPRL1 (0.47) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8327212 | 0.72 | HTR2B (0.59) | KDM4EBCHEACHEMEN1KMT2A | |
| SCHEMBL612712 | 0.71 | OPRL1 (0.52) | ALDH1A1HSD17B10CYP1A2GAAMEN1 | |
| SCHEMBL29732524 | 0.70 | CHRM2 (0.46) | KDM4ECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL22720966 | 0.70 | CHRM2 (0.46) | KDM4ECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4143774 | 0.70 | SIGMAR1 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7081194 | 0.69 | TXNRD1 (0.38) | KDM4EALDH1A1HSD17B10TDP1HPGD | |
| SCHEMBL18115398 | 0.68 | CHRM2 (0.44) | KDM4EALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL14403245 | 0.68 | DRD2 (0.39) | KDM4EALDH1A1SLC6A3SLC6A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | KDM4E 2515/4885ALDH1A1 828/4885CHRM2 1911/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | KDM4E 2515/4885ALDH1A1 828/4885CHRM2 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.